The Senate Finance Committee today held a hearing for Alex Azar, President Trump’s nominee for secretary of Health and Human Services. Azar, former president of Lilly USA and deputy HHS secretary under the George W. Bush administration, faced a number of questions from senators about his ties to the pharmaceutical industry and how he would tackle high drug prices. If confirmed, Azar said he would focus his efforts on addressing the high cost of drugs; making health care more affordable, available and “tailored to what individuals want and need in their care”; harnessing “the power of Medicare to shift the focus in our health care system from paying for procedures and sickness to paying for health and outcomes”; and tackling “the scourge of the opioid epidemic.” Tom Price, M.D., resigned as HHS secretary last September. Deputy Secretary Eric Hargan has been serving as acting secretary.

Headline
In a commentary published March 26 by Healthcare Dive, AHA President and CEO Rick Pollack details why a new facility administrative policy from Anthem will…
Perspective
Public
From birth to death, from critical injuries to elective surgeries, from crisis and disaster to community food banks and health improvement initiatives —…
Headline
The Coalition to Strengthen America’s Healthcare March 18 launched a new ad highlighting harmful practices by large corporate health insurers that drive up…
Headline
America’s hospitals and health systems are deeply committed to providing high-quality, accessible and affordable care, AHA President and CEO Rick Pollack March…
Blog
Public
As seen in the Wall Street Journal.Hospitals are the heart of communities across America for one fundamental reason: They support patients whenever, wherever…
Headline
The AHA commented March 13 on the Centers for Medicare & Medicaid Services’ proposed Notice of Benefit and Payment Parameters for 2027. The…